Search | Clinical Trials Finder

Conditions: Healthy
Interventions: PF-06651600, Ethinyl estradiol (EE) and levonorgestrel(LN); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 2
States / cities: Coral Gables, Florida • Miami, Florida

Conditions: Dry Eye
Interventions: Systane Complete PF, Refresh Relieva PF, Refresh Optive Mega-3 PF, CVS Health Lubricant Eye Drop (PG 0.6%); Drug
Lead sponsor: University of California, Berkeley; Other
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Berkeley, California

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo, PF-04603629; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 2
States / cities: Phoenix, Arizona • San Antonio, Texas

Conditions: Malaria
Interventions: PfSPZ Vaccine, CHMI (7G8), CHMI (NF135.C10); Biological
Lead sponsor: Sanaria Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Baltimore, Maryland • Silver Spring, Maryland

Conditions: Knee Arthropathy
Interventions: Bupivacaine with epinephrine, Methylprednisolone, Cefazolin, 8 MHz. Chiba needle, Bupivacaine with Dexamethasone, Bupivacaine 25cc, Bupivacaine 20cc, Dexamethasone; Drug · Device
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 80 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Phase 1 Sickle Cell
Interventions: PDE9i, placebo for PDE9i; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 12
States / cities: Chicago, Illinois • Boston, Massachusetts • Brooklyn, New York + 2 more

Conditions: Depressive Symptoms
Interventions: Surveys, Supportive Text messages, Personalized Feedback (PF) Report; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 17 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Atrial Fibrillation
Interventions: Sotalol, Dofetilide; Drug
Lead sponsor: Samir Saba; Other
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Alzheimer's Disease, Huntington's Disease
Interventions: Dimebon; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 2
States / cities: Miami, Florida • Saint Paul, Minnesota

Conditions: Pancreatic Cancer, Cancer Cachexia
Interventions: Baseline Lifestyle and Symptom Assessment, Extended Lifestyle Monitoring, Feasibility Survey; Other
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Chronic Kidney Disease
Interventions: Sodium bicarbonate, Placebos; Drug
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 21 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Dry Eye Syndromes
Interventions: Carboxymethylcellulose (CMC) Artificial Tears, Preservative-free, CMC-free Artificial Tears (control); Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 100 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Male Breast Carcinoma, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma
Interventions: Bevacizumab, Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel; Biological · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 454 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2025
U.S. locations: 448
States / cities: Jonesboro, Arkansas • Rogers, Arkansas • Berkeley, California + 309 more

Conditions: EBV-Related Post-Transplant Lymphoproliferative Disorder, Monomorphic Post-Transplant Lymphoproliferative Disorder, Polymorphic Post-Transplant Lymphoproliferative Disorder, Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder, Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder, Refractory Monomorphic Post-Transplant Lymphoproliferative Disorder, Refractory Polymorphic Post-Transplant Lymphoproliferative Disorder
Interventions: Allogeneic LMP1/LMP2-Specific Cytotoxic T-Lymphocytes, Rituximab; Biological
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 29 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 38
States / cities: Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 34 more

Conditions: Malaria
Interventions: Mefloquine, Control; Drug · Other
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 55 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Lupus Erythematosus, Systemic, Lupus Erythematosus, Cutaneous
Interventions: Placebo, PF-06823859; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 11
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 4 more

Conditions: Combined Hepatocellular Carcinoma and Cholangiocarcinoma, Stage III Liver Cancer, Stage IV Liver Cancer
Interventions: Atezolizumab, Bevacizumab, Biospecimen Collection, Cisplatin, Computed Tomography, Conventional Magnetic Resonance Imaging, Gemcitabine Hydrochloride; Biological · Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 37
States / cities: Auburn, California • Berkeley, California • Fremont, California + 27 more

Conditions: Obesity, Overweight and/or Obesity, Overweight, Drug Interaction
Interventions: PF-08653944, Acetaminophen; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Orthopedic Disorder
Interventions: Pre-Visit Messages; Other
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 291 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Pulmonary Fibrosis Secondary to Systemic Sclerosis, Pulmonary Fibrosis, Interstitial Lung Disease, Interstitial Lung Disease, Interstitial Lung Disease Due to Connective Tissue Disease (Disorder), Interstitial Lung Disease in Patients With Rheumatoid Arthritis, Interstitial Lung Disease With Progressive Fibrotic Phenotype in Diseases Classified Elsewhere, Hypersensitivity Pneumonitis, Interstitial Lung Disease With Systemic Sclerosis
Interventions: AP01, Placebo; Drug · Other
Lead sponsor: Avalyn Pharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 375 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 61
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 46 more

Conditions: Human Immunodeficiency Virus, Hypertension
Interventions: Task-shifting strategy for HTN control (TASSH) protocol; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 85 Years
Enrollment: 830 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Anesthesia
Interventions: Dural puncture epidurals (DPE), Traditional epidurals (EPI), Combined-spinal epidural technique (CSE); Procedure
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Presbyopia
Interventions: BRIMOCHOL™ PF, Carbachol PF, Brimonidine tartrate; Drug
Lead sponsor: Visus Therapeutics; Other
Eligibility: 45 Years to 80 Years
Enrollment: 182 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 15
States / cities: Glendale, California • Rancho Cordova, California • Jacksonville, Florida + 10 more

Conditions: Healthy
Interventions: PF-06946860, Placebo; Biological · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: New Haven, Connecticut

Search by objective public record fields.

Effect of PF-06651600 on the Pharmacokinetics of Oral Contraceptive Steroids

Artificial Tears, Tear Lipids and Tear Film Dynamics

Single-Dose Study Of PF-04603629 In Type 2 Diabetic Subjects

PfSPZ Vaccine: Dose Optimization With Heterologous Challenge in Healthy Malaria-Naïve Adults

Adductor Canal Block With Periarticular Injection and IPACK (ACB/PAI/IPACK) Versus Periarticular Injection (PAI)

Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Study Of PF-04447943, Co-Administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease

College Student Stress: Transitions Over Time

Improvement in Endothelial Dysfunction After Initiation of Anti-arrhythmic Therapy in Atrial Fibrillation Patients

A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired And Normal Renal Function

A First-in-Human Study of FID-022 in Solid Tumor Patients

Sodium Bicarbonate Supplementation in Chronic Kidney Disease Evaluation of Dose Response, Safety and Beneficial Effects

Effects of Carboxymethylcellulose Artificial Tears on the Eye Microbiome

Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery

Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder

Merozoite Surface Protein 1 Antibody Response in Asymptomatic Human Malaria Infection

A Study to Learn About the Study Medicine (PF-06823859) in Adults With Active CLE or SLE With Skin Symptoms.

A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer

A Study to Learn About the Effect of Study Medicine Called PF-08653944 on How Quickly the Stomach Empties Its Content in Healthy Adults With Overweight or Obesity

Pre-visit Digital Messaging Improves Patient Reported Outcome Measure Participation Prior to the Orthopedic Ambulatory Visit

A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis

Integration of Hypertension Management Into HIV Care in Nigeria

Epidural Technique: Does it Really Matter to the Patient?

Safety and Efficacy Study BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic or Pseudophakic Presbyopia

Singe Dose, First in Human Study of PF- 06946860 in Healthy Adult Subjects